Table 4

Multivariate analysis for leukemia-free survival (LFS) in patients who underwent a URD or HLA-identical sibling transplantation for AML, ALL, and CML

FactorsRelative risk95% CIP
AML*    
    URD vs sib (no acute GVHD) 2.02 1.61-2.53 < .001 
    URD vs sib (acute GVHD present) 1.27 0.98-1.65 .072 
    Chronic GVHD 1.08 0.89-1.31 .45 
ALL    
    URD vs sib 1.02 0.82-1.29 .84 
    Acute GVHD 1.14 0.92-1.42 .23 
    Chronic GVHD 1.12 0.86-1.46 .41 
CML    
    URD vs sib 0.95 0.80-1.14 .59 
    Acute GVHD 1.91 1.64-2.22 < .001 
    Chronic GVHD 1.21 1.01-1.47 .043 
FactorsRelative risk95% CIP
AML*    
    URD vs sib (no acute GVHD) 2.02 1.61-2.53 < .001 
    URD vs sib (acute GVHD present) 1.27 0.98-1.65 .072 
    Chronic GVHD 1.08 0.89-1.31 .45 
ALL    
    URD vs sib 1.02 0.82-1.29 .84 
    Acute GVHD 1.14 0.92-1.42 .23 
    Chronic GVHD 1.12 0.86-1.46 .41 
CML    
    URD vs sib 0.95 0.80-1.14 .59 
    Acute GVHD 1.91 1.64-2.22 < .001 
    Chronic GVHD 1.21 1.01-1.47 .043 

LFS is decreased in URD transplantations for AML without acute GVHD but is similar between URD and sib transplants for ALL and CML. RR for reference group (sib) is 1.0.

URD indicates unrelated donor; sib, HLA-identical sibling; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; GVHD, graft-versus-host disease; CI, confidence interval; WBC, white blood cell; and CR1, first complete remission.

*

Interaction present between donor source and aGVHD. Model also adjusted for GVHD prophylaxis, WBC count, duration of CR1, and cytogenetics and stratified by disease stage, graft type, and Karnofsky score.

Model also adjusted for patient's age and stratified by disease stage, graft type, and Karnofsky score.

Model also adjusted for patient age and time from diagnosis to transplantation, and stratified by disease stage, graft type, and Karnofsky score.

Close Modal

or Create an Account

Close Modal
Close Modal